The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oral Delivery Update

18 Dec 2023 07:00

RNS Number : 0368X
N4 Pharma PLC
18 December 2023
 

 

18 December 2023

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Oral Delivery Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a positive update on its ongoing oral delivery research work.

 

The Company through its research program with the University of Queensland is evaluating the potential of Nuvec® to act as an oral delivery system for oligonucleotides including DNA and RNA.

 

Experiments have now confirmed, in vivo, the successful oral administration of Nuvec® loaded with a DNA plasmid for ovalbumin. The Nuvec® was administered by enteric coated capsule and the contents, having been released in the intestinal lumen, were taken up by intestinal cells, with successful transfection and release of the newly synthesized ovalbumin.

 

Specifically, the first experiment was a repeat of a study conducted earlier this year whereby an enterically coated capsule containing Nuvec® loaded with a DNA plasmid for ovalbumin was administered and protein expression was observed after 3 days. In this recent experiment, an additional second capsule was administered on day 3 which resulted in a much higher peak level of expression on days 4-7.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"This continued success shows that Nuvec® has the potential to be successfully used as an oral delivery system with many potential applications such as a vaccine, a product for Irritable Bowel Disease or to treat colonic cancer among many possible examples. Given the complexities involved in oral delivery this early success with Nuvec® represents a potentially massive opportunity and point of difference for Nuvec® and its use as delivery system to target multiple diseases.

 

"With this new data we are in the process of scoping out the next phase of work to accumulate sufficient data to enable us to focus on a specific oral application and further news on this will be announced in the new year and we expect to make advancing Nuvec's® use as an oral delivery technology a key priority for 2024. In the meantime, the University of Queensland will continue its work exploring the use of Nuvec® as an oral delivery system for vaccines as part of our Australian Research Council funded grant with them."

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

 

Engage with us directly at N4 Pharma Investor Hub

 

Via N4 Pharma Investor Hub

 

 

Sign up at investors.n4pharma.com

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44(0)20 3657 0050

IFC Advisory Ltd

Financial PR

Graham Herring

Zach Cohen

Tel: +44(0)20 3934 6630

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre?clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFLFIIEDSESE
Date   Source Headline
25th Feb 20207:00 amRNSFinal Results
11th Feb 20207:00 amRNSResearch Collaboration Agreement
29th Jan 20207:00 amRNSUpdate on Nuvec® process improvements
18th Sep 20197:00 amRNSInterim Results
20th Aug 20197:00 amRNSResults of University of Queensland Study
13th Aug 201911:16 amRNSHolding(s) in Company
15th Jul 20192:05 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
3rd Jul 20194:40 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jun 201912:51 pmRNSResult of AGM
19th Jun 20197:00 amRNSAGM Statement
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:36 pmRNSPrice Monitoring Extension
28th May 20192:21 pmRNSChange to Director Shareholding
22nd May 20197:00 amRNSPosting of Annual Report and Notice of AGM
21st May 20197:00 amRNSBoard Changes
14th May 20197:00 amRNSFinal Results
15th Apr 20197:00 amRNSNuvec® Research update
10th Apr 201911:52 amRNSDirector/PDMR Shareholding
9th Apr 20197:00 amRNSNuvec® Research update
20th Mar 20199:40 amRNSHolding(s) in Company
20th Mar 20199:40 amRNSHolding(s) in Company
28th Feb 20195:00 pmRNSTotal Voting Rights
14th Feb 20192:14 pmRNSHolding(s) in Company
8th Feb 201912:23 pmRNSPlacing to raise £1.05 million
20th Dec 20187:00 amRNSNuvec licence extension
28th Nov 20187:00 amRNSNuvec® research update
16th Nov 20181:36 pmRNSNuvec resource changes
15th Nov 20187:00 amRNSFiling of further Nuvec® patent application
14th Nov 201811:05 amRNSSecond Price Monitoring Extn
14th Nov 201811:00 amRNSPrice Monitoring Extension
14th Nov 20189:05 amRNSSecond Price Monitoring Extn
14th Nov 20189:00 amRNSPrice Monitoring Extension
8th Nov 20184:40 pmRNSSecond Price Monitoring Extn
8th Nov 20184:35 pmRNSPrice Monitoring Extension
8th Nov 20182:05 pmRNSSecond Price Monitoring Extn
8th Nov 20182:00 pmRNSPrice Monitoring Extension
5th Nov 201811:06 amRNSSecond Price Monitoring Extn
5th Nov 201811:00 amRNSPrice Monitoring Extension
5th Nov 20189:00 amRNSPrice Monitoring Extension
5th Nov 20187:54 amRNSResearch collaboration update
29th Oct 20187:00 amRNSNuvec® research update
2nd Oct 201811:44 amRNSResearch collaboration for novel DNA vaccine
26th Sep 20181:48 pmRNSGrant of options
26th Sep 201811:00 amRNSPrice Monitoring Extension
24th Sep 20184:41 pmRNSSecond Price Monitoring Extn
24th Sep 20184:35 pmRNSPrice Monitoring Extension
24th Sep 20182:05 pmRNSSecond Price Monitoring Extn
24th Sep 20182:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.